Argenica Therapeutics Ltd
AASX:AGN0.11
AUD
-0.01
(-8.33%)
ISIN
AU0000150328
Return %
Stock
S&P 500
1Y
-63.33
14.20
3Y
-68.57
81.12
5Y
-69.86
68.34
Capital Structure
AUD
•
in mil. unless spec.Working Capital
AUD
•
in mil. unless spec.Growth Rates
AUD
•
in mil. unless spec.Semi-annual Revenue
AUD
•
in mil. unless spec.Semi-annual Earnings Per Share
AUD
•
in mil. unless spec.Semi-annual Dividends Per Share
AUD
•
in mil. unless spec.Company Description
- CEO
- Liz Dallimore
- Full Time Employees
- 7
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 117 Broadway Nedlands WA Australia 6009
- IPO Date
- Jun 9, 2021
- Website
- argenica.com.au
- Similar Companies
- Business
- Argenica Therapeutics Limited is an Australian biotechnology company specializing in the research, development, and commercialization of novel neuroprotective therapeutics aimed at reducing brain damage following acute central nervous system injuries such as stroke, traumatic brain injury, and hypoxic ischaemic encephalopathy. The company's core product is ARG-007, a cationic, arginine-rich peptide demonstrated in preclinical models to reduce brain cell death and has successfully completed Phase 1 clinical trials showing safety and tolerability in healthy human volunteers. ARG-007 is currently undergoing a Phase 2 clinical trial in acute ischemic stroke patients across Australia, aiming to establish safety and efficacy for use as an early intervention therapeutic that can be administered by first responders prior to hospital arrival. Founded in November 2019 and headquartered in Nedlands, Western Australia, Argenica collaborates closely with the University of Western Australia and the Perron Institute for Neurological and Translational Science, drawing on pioneering research to develop its lead drug candidate. The company operates primarily in Australia with a focus on advancing its drug through regulated clinical development phases towards commercialization. Recent major developments include the successful completion of a $12 million capital placement in April 2024, advancing patient dosing in the Phase 2 stroke trial, and the receipt of ethics approvals for continued clinical testing. Argenica's ARG-007 has shown further promising efficacy in preclinical stroke studies and gained significant non-dilutive funding for research in related neurological conditions. The company is positioning itself for strategic partnerships, licensing, co-development, or acquisition by larger pharmaceutical companies following favorable Phase 2 results, aiming to leverage global commercialization channels. Argenica also broadened its pipeline development efforts into other neurological indications based on ARG-007’s mechanism of action, supported by its ongoing collaborations and research grants. Thus, Argenica Therapeutics Limited develops and commercializes ARG-007, a novel neuroprotective drug candidate for acute ischemic stroke and related brain injuries, supported by clinical advancement, strategic funding, and research partnerships, centered on improving patient outcomes through early intervention therapeutics. This description incorporates the company's main products and services, geographic and developmental context, and highlights recent strategic and clinical progress relevant to investors and stakeholders.
Company News
Brainomix AI Technology Reveals Efficacy of Novel Neuroprotective Drug Candidate in Severe Acute Ischemic Stroke Patients